Equities analysts expect Savara Inc (NASDAQ:SVRA) to post ($0.44) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Savara’s earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.41). Savara reported earnings per share of ($0.37) during the same quarter last year, which suggests a negative year-over-year growth rate of 18.9%. The company is scheduled to report its next quarterly earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Savara will report full year earnings of ($1.65) per share for the current year, with EPS estimates ranging from ($1.82) to ($1.48). For the next year, analysts anticipate that the company will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.74) to ($0.64). Zacks’ EPS calculations are an average based on a survey of research firms that cover Savara.
Savara (NASDAQ:SVRA) last released its earnings results on Thursday, August 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05.
In other Savara news, Director David A. Ramsay purchased 58,357 shares of the business’s stock in a transaction dated Friday, June 28th. The shares were acquired at an average price of $2.37 per share, for a total transaction of $138,306.09. Following the acquisition, the director now owns 64,685 shares of the company’s stock, valued at $153,303.45. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David A. Ramsay purchased 40,215 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were acquired at an average price of $2.37 per share, for a total transaction of $95,309.55. Following the acquisition, the director now directly owns 23,570 shares in the company, valued at approximately $55,860.90. The disclosure for this purchase can be found here. Insiders have bought a total of 99,472 shares of company stock worth $235,758 in the last 90 days. 6.50% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in SVRA. Nomura Holdings Inc. acquired a new position in Savara in the 2nd quarter valued at $496,000. Marshall Wace North America L.P. acquired a new position in Savara in the 2nd quarter valued at $190,000. Vanguard Group Inc. grew its stake in Savara by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,250,254 shares of the company’s stock valued at $2,963,000 after buying an additional 10,794 shares during the last quarter. Farallon Capital Management LLC grew its stake in Savara by 43.3% in the 2nd quarter. Farallon Capital Management LLC now owns 3,475,000 shares of the company’s stock valued at $8,236,000 after buying an additional 1,050,000 shares during the last quarter. Finally, Eversept Partners LP acquired a new position in Savara in the 2nd quarter valued at $574,000. Institutional investors and hedge funds own 39.18% of the company’s stock.
SVRA stock traded down $0.01 during midday trading on Wednesday, reaching $2.31. The company had a trading volume of 216,410 shares, compared to its average volume of 388,905. Savara has a 1 year low of $2.16 and a 1 year high of $11.96. The company has a current ratio of 12.61, a quick ratio of 12.61 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $95.17 million, a P/E ratio of -1.79 and a beta of 0.21. The company has a 50 day moving average of $2.49 and a two-hundred day moving average of $6.79.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More: What is the Beige Book?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.